FDA Approves Relacorilant With Nab-paclitaxel For Platinum-resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

The FDA has approved Relacorilant in combination with Nab-paclitaxel for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This approval marks a significant advancement in treatment options for patients with these types of cancer. The stock ticker for the company associated with this drug is CORT.